{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:03:46Z","timestamp":1791122626482,"version":"4.1.0"},"reference-count":48,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Third-generation aromatase inhibitors (AIs)\u2014anastrozole, letrozole, and exemestane\u2014are standard adjuvant endocrine therapy for women with postmenopausal hormone receptor (HR)\u2013positive early-stage breast cancer. However, little is known about their comparative effectiveness in clinical settings.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare adjuvant anastrozole, letrozole, and exemestane in terms of disease-free survival (DFS) and overall survival (OS) in women with postmenopausal HR-positive early-stage breast cancer.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This comparative effectiveness study conducted in France emulated a target trial using national medicoadministrative data. The patient cohort was derived from the updated French Early Breast Cancer Cohort and consisted of women aged 50 to 75 years with early-stage breast cancer who were diagnosed between January 1, 2011, and December 31, 2020, and followed up through December 31, 2021. All women initiated adjuvant AI therapy without ovarian suppression. Data analysis was performed from November 2024 to May 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Upfront adjuvant anastrozole, letrozole, and exemestane, evaluated under natural persistence and under a hypothetical intervention ensuring perfect persistence for 5 years.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end points were DFS and OS. Both DFS and OS were estimated using adjusted Kaplan-Meier curves.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 148\u202f436 women (median [IQR] age, 64 [59-69] years) included in the analyses, 38.5% initiated anastrozole, 52.9% initiated letrozole, and 8.5% initiated exemestane. After a median (IQR) follow-up of 63 (34-94) months, the 8-year DFS under natural persistence was estimated to be lower for the exemestane group (79.1%; 95% CI, 78.1%-80.0%) compared with the anastrozole (81.0%; 95% CI, 80.6%-81.5%) and letrozole (81.1%; 95% CI, 80.7%-81.5%) groups. Similarly, the 8-year OS was 88.8% (95% CI, 88.0%-89.6%) for the exemestane group compared with 90.5% (95% CI, 90.2%-90.8%) for the anastrozole group and 89.9% (95% CI, 89.6%-90.2%) for the letrozole group. Patients who initiated exemestane were also more likely to discontinue treatment within 5 years of therapy than their counterparts taking the other AIs (39.3% [95% CI, 38.3%-40.3%] in the exemestane group vs 35.1% [95% CI, 34.7%-35.6%] in the anastrozole group and 35.0% [95% CI, 34.6%-35.4%] in the letrozole group). However, the lower DFS and OS observed for exemestane compared with letrozole and anastrozole persisted under perfect persistence.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The findings of this comparative effectiveness study using a target trial emulation framework suggest that adjuvant endocrine therapy with exemestane may result in slightly lower DFS and OS compared with anastrozole and letrozole in patients with postmenopausal HR-positive early-stage breast cancer. The findings favor anastrozole or letrozole as initial treatment and highlight the need for future studies to inform AI selection.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.50842","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T16:30:49Z","timestamp":1766766649000},"page":"e2550842","source":"Crossref","is-referenced-by-count":7,"title":["Outcomes of Anastrozole, Letrozole, and Exemestane in Patients With Postmenopausal Breast Cancer"],"prefix":"10.1001","volume":"8","author":[{"given":"Elise","family":"Dumas","sequence":"first","affiliation":[{"name":"Institute of Mathematics, \u00c9cole Polytechnique F\u00e9d\u00e9rale de Lausanne, Lausanne, Switzerland"},{"name":"Residual Tumor and Response to Treatment Laboratory, RT2Lab, Translational Research Department, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), U932 Immunity and Cancer, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Hamy","sequence":"additional","affiliation":[{"name":"Residual Tumor and Response to Treatment Laboratory, RT2Lab, Translational Research Department, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), U932 Immunity and Cancer, Universit\u00e9 Paris Cit\u00e9, Paris, France"},{"name":"Department of Medical Oncology, Institut Curie, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerollos Nashat","family":"Wanis","sequence":"additional","affiliation":[{"name":"Departments of Breast Surgical Oncology and Health Services Research and Institute for Data Science in Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floriane","family":"Jochum","sequence":"additional","affiliation":[{"name":"Residual Tumor and Response to Treatment Laboratory, RT2Lab, Translational Research Department, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), U932 Immunity and Cancer, Universit\u00e9 Paris Cit\u00e9, Paris, France"},{"name":"Department of Gynecology, Strasbourg University Hospital, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Coussy","sequence":"additional","affiliation":[{"name":"Residual Tumor and Response to Treatment Laboratory, RT2Lab, Translational Research Department, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), U932 Immunity and Cancer, Universit\u00e9 Paris Cit\u00e9, Paris, France"},{"name":"Department of Medical Oncology, Institut Curie, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Giacchetti","sequence":"additional","affiliation":[{"name":"S\u00e9nopole, H\u00f4pital Saint-Louis, Assistance Publique\u2013H\u00f4pitaux de Paris (AP-HP), Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gaillard","sequence":"additional","affiliation":[{"name":"Residual Tumor and Response to Treatment Laboratory, RT2Lab, Translational Research Department, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), U932 Immunity and Cancer, Universit\u00e9 Paris Cit\u00e9, Paris, France"},{"name":"Department of Surgical Oncology, Universit\u00e9 Paris Cit\u00e9, Institut Curie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enora","family":"Laas","sequence":"additional","affiliation":[{"name":"Residual Tumor and Response to Treatment Laboratory, RT2Lab, Translational Research Department, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), U932 Immunity and Cancer, Universit\u00e9 Paris Cit\u00e9, Paris, France"},{"name":"Department of Surgical Oncology, Universit\u00e9 Paris Cit\u00e9, Institut Curie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Houzard","sequence":"additional","affiliation":[{"name":"Health Data and Assessment, Health Survey Data Science and Assessment Division, Institut National du Cancer (INCa), Boulogne-Billancourt, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Le Bihan-Benjamin","sequence":"additional","affiliation":[{"name":"Health Data and Assessment, Health Survey Data Science and Assessment Division, Institut National du Cancer (INCa), Boulogne-Billancourt, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Reyal","sequence":"additional","affiliation":[{"name":"Residual Tumor and Response to Treatment Laboratory, RT2Lab, Translational Research Department, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), U932 Immunity and Cancer, Universit\u00e9 Paris Cit\u00e9, Paris, France"},{"name":"Department of Surgical Oncology, Universit\u00e9 Paris Cit\u00e9, Institut Curie, Paris, France"},{"name":"Department of Surgery, Institut Jean Godinot, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Gougis","sequence":"additional","affiliation":[{"name":"Residual Tumor and Response to Treatment Laboratory, RT2Lab, Translational Research Department, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), U932 Immunity and Cancer, Universit\u00e9 Paris Cit\u00e9, Paris, France"},{"name":"Department of Medical Oncology, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Sorbonne Universit\u00e9, Institut Universitaire du Cancer, Paris, France"},{"name":"Clinical Investigation Center (CIC-1901), INSERM, Department of Pharmacology, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats Julius","family":"Stensrud","sequence":"additional","affiliation":[{"name":"Institute of Mathematics, \u00c9cole Polytechnique F\u00e9d\u00e9rale de Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"zoi251355r1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: global statistics for 2020 and 2040.","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast"},{"issue":"6","key":"zoi251355r2","first-page":"477","article-title":"Breast cancer statistics 2024.","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"zoi251355r3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review.","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"issue":"9472","key":"zoi251355r4","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2005","journal-title":"Lancet"},{"key":"zoi251355r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107607","article-title":"Aromatase inhibitors for the treatment of breast cancer: an overview (2019-2023).","volume":"151","author":"Bhatia","year":"2024","journal-title":"Bioorg Chem"},{"issue":"12","key":"zoi251355r7","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.","volume":"11","author":"Cuzick","year":"2010","journal-title":"Lancet Oncol"},{"issue":"26","key":"zoi251355r8","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1056\/NEJMoa052258","article-title":"A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.","volume":"353","author":"Th\u00fcrlimann","year":"2005","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi251355r9","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.","volume":"350","author":"Coombes","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi251355r10","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"issue":"9","key":"zoi251355r12","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1002\/cncr.10908","article-title":"An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.","volume":"95","author":"Buzdar","year":"2002","journal-title":"Cancer"},{"issue":"24","key":"zoi251355r13","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMra023246","article-title":"Aromatase inhibitors in breast cancer.","volume":"348","author":"Smith","year":"2003","journal-title":"N Engl J Med"},{"key":"zoi251355r14","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.breast.2004.09.003","article-title":"Are all aromatase inhibitors the same? A review of the current evidence.","author":"J\u00e4nicke","year":"2004","journal-title":"Breast"},{"issue":"2","key":"zoi251355r15","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10549-024-07313-x","article-title":"Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane.","volume":"206","author":"Bertelsen","year":"2024","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"zoi251355r16","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s10549-016-4077-4","article-title":"Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.","volume":"161","author":"Robarge","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"zoi251355r17","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920925991","article-title":"Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study.","volume":"12","author":"Wang","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"7","key":"zoi251355r18","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ctrv.2006.07.012","article-title":"Safety of adjuvant aromatase inhibitor therapy.","volume":"32","author":"Venturini","year":"2006","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"zoi251355r19","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1517\/14656560902953738","article-title":"Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer.","volume":"10","author":"Nabholtz","year":"2009","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"zoi251355r20","doi-asserted-by":"publisher","first-page":"R52","DOI":"10.1186\/bcr1757","article-title":"Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.","volume":"9","author":"Goss","year":"2007","journal-title":"Breast Cancer Res"},{"issue":"4","key":"zoi251355r21","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S1470-2045(18)30116-5","article-title":"Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.","volume":"19","author":"De Placido","year":"2018","journal-title":"Lancet Oncol"},{"issue":"11","key":"zoi251355r22","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1200\/JCO.2012.44.7805","article-title":"Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27\u2013a randomized controlled phase III trial.","volume":"31","author":"Goss","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"zoi251355r23","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1200\/JCO.2016.69.2871","article-title":"Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor-positive, node-positive early breast cancer: final results of the randomized phase III Femara Versus Anastrozole Clinical Evaluation (FACE) trial.","volume":"35","author":"Smith","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi251355r24","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1200\/JCO.18.01160","article-title":"Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO Clinical Practice Guideline focused update.","volume":"37","author":"Burstein","year":"2019","journal-title":"J Clin Oncol"},{"issue":"13","key":"zoi251355r26","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1056\/NEJM197809282991304","article-title":"The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 \u201cnegative\u201d trials.","volume":"299","author":"Freiman","year":"1978","journal-title":"N Engl J Med"},{"key":"zoi251355r27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jss.2018.02.014","article-title":"Sample size of surgical randomized controlled trials: a lack of improvement over time.","volume":"228","author":"Ahmed Ali","year":"2018","journal-title":"J Surg Res"},{"issue":"2","key":"zoi251355r28","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s10549-012-2114-5","article-title":"Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review.","volume":"134","author":"Murphy","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"zoi251355r29","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/j.1524-4733.2009.00600.x","article-title":"Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report\u2013Part I.","volume":"12","author":"Berger","year":"2009","journal-title":"Value Health"},{"issue":"11","key":"zoi251355r30","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.3390\/cancers14112671","article-title":"The French Early Breast Cancer Cohort (FRESH): a resource for breast cancer research and evaluations of oncology practices based on the French National Healthcare System Database (SNDS).","volume":"14","author":"Dumas","year":"2022","journal-title":"Cancers (Basel)"},{"key":"zoi251355r31","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","article-title":"Value of a national administrative database to guide public decisions: from the Syst\u00e8me National d\u2019Information Interr\u00e9gimes de l\u2019Assurance Maladie (SNIIRAM) to the Syst\u00e8me National des Donn\u00e9es de Sant\u00e9 (SNDS) in France.","volume":"65","author":"Tuppin","year":"2017","journal-title":"Rev Epidemiol Sante Publique"},{"issue":"10","key":"zoi251355r32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206448","article-title":"Cancer care and public health policy evaluations in France: usefulness of the national cancer cohort.","volume":"13","author":"Bousquet","year":"2018","journal-title":"PLoS One"},{"key":"zoi251355r33","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","article-title":"Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses.","volume":"79","author":"Hern\u00e1n","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"zoi251355r34","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available.","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"zoi251355r35","doi-asserted-by":"publisher","first-page":"k182","DOI":"10.1136\/bmj.k182","article-title":"How to estimate the effect of treatment duration on survival outcomes using observational data.","volume":"360","author":"Hern\u00e1n","year":"2018","journal-title":"BMJ"},{"issue":"2","key":"zoi251355r36","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10549-010-1132-4","article-title":"Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer.","volume":"126","author":"Hershman","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"zoi251355r37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087027","article-title":"Interruption and non-adherence to long-term adjuvant hormone therapy is associated with adverse survival outcome of breast cancer women\u2013an Asian population-based study.","volume":"9","author":"Hsieh","year":"2014","journal-title":"PLoS One"},{"key":"zoi251355r38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102264","article-title":"Systematic review of real-world studies evaluating the impact of medication non-adherence to endocrine therapies on hard clinical endpoints in patients with non-metastatic breast cancer.","volume":"100","author":"Inotai","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"16","key":"zoi251355r39","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1200\/JCO.24.01131","article-title":"Explaining the relationships between age, endocrine therapy persistence, and risk of recurrence in hormone receptor\u2013positive early breast cancer: a nationwide cohort study.","volume":"43","author":"Dumas","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi251355r40","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/annonc\/mdq337","article-title":"The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum.","volume":"22","author":"L\u00f8nning","year":"2011","journal-title":"Ann Oncol"},{"issue":"12","key":"zoi251355r41","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-19-3091","article-title":"Anastrozole has an association between degree of estrogen suppression and outcomes in early breast cancer and is a ligand for estrogen receptor a.","volume":"26","author":"Ingle","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"11","key":"zoi251355r42","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1158\/1535-7163.MCT-07-0312","article-title":"Exemestane\u2019s 17-hydroxylated metabolite exerts biological effects as an androgen.","volume":"6","author":"Ariazi","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"zoi251355r43","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10549-014-3082-8","article-title":"AR collaborates with ERa in aromatase inhibitor-resistant breast cancer.","volume":"147","author":"Rechoum","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"zoi251355r44","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1677\/ERC-09-0257","article-title":"Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment.","volume":"17","author":"Takagi","year":"2010","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"zoi251355r45","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1177\/0091270011424153","article-title":"Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole.","volume":"52","author":"Bell","year":"2012","journal-title":"J Clin Pharmacol"},{"issue":"22","key":"zoi251355r46","doi-asserted-by":"publisher","first-page":"5126","DOI":"10.1200\/JCO.2005.07.097","article-title":"Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.","volume":"23","author":"L\u00f8nning","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi251355r47","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s40618-022-01911-6","article-title":"The association of serum testosterone with dyslipidemia is mediated by obesity: the Henan Rural Cohort Study.","volume":"46","author":"Fan","year":"2023","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"zoi251355r48","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S1470-2045(14)70035-X","article-title":"Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.","volume":"15","author":"Goss","year":"2014","journal-title":"Lancet Oncol"},{"key":"zoi251355r6","volume-title":"StatPearls","author":"Peters","year":"2024"},{"key":"zoi251355r25","volume-title":"Causal Inference: What If","author":"Hern\u00e1n","year":"2020"},{"key":"zoi251355r11","unstructured":"SENORIF (R\u00e9f\u00e9rentiel Francilien de Pathologie Mammaire). Cancers et pathologies du sein: attitudes diagnostiques et therapeutiques, protocoles de traitement 2021-2022. Accessed April 3, 2025. https:\/\/www.gustaveroussy.fr\/sites\/default\/files\/referentiel-senorif-2021-2022.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2843178\/dumas_2025_oi_251355_1765989495.61041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T16:30:50Z","timestamp":1766766650000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2843178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.50842","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]}}}